Manusiran sodium

Manusiran (3 mg/kg; subcutaneous injection; single dose) sodium potently inhibits hepatic Tmprss6 expression for at least 3 weeks and increases hepcidin levels in healthy C57BL/6N mice^[2].
Single administration of Manusiran (1-3 mg/kg) sodium dose-dependently inhibits hepatic Tmprss6 expression, increases hepcidin levels, normalizes or reduces systemic iron parameters, corrects erythroid parameters, and elevates splenic iron content in Hfe-knockout mice with hereditary hemochromatosis type 1^[2].
Single administration of Manusiran (3 mg/kg) sodium or subcutaneous administration of Manusiran (3 mg/kg once every 3 weeks for a total of 6 weeks) sodium potently inhibits hepatic Tmprss6 expression, reduces systemic iron levels, and normalizes erythroid parameters in aged Hfe knockout mice with type 1 hereditary hemochromatosis, with the effects lasting up to 6 weeks; when combined with deferiprone, it further enhances deferiprone-mediated reduction of hepatic iron^[2].
Manusiran (3 mg/kg; subcutaneous injection; administered on day 1 and day 14; 2 doses) sodium potently inhibits Tmprss6 expression in the liver of β-thalassemic Hbb^th3/+ mice, restores hepcidin levels to normal, reduces serum iron by 70%, improves red blood cell parameters, alleviates ineffective erythropoiesis and splenomegaly, and restores zinc/magnesium homeostasis in the spleen; when combined with deferiprone, its hepatic iron clearance effect is further enhanced^[3].